Literature DB >> 31810584

Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease.

Irene Rosas1, Carmen Martínez2, Jordi Clarimón3, Alberto Lleó3, Ignacio Illán-Gala3, Oriol Dols-Icardo3, Barbara Borroni4, Maria Rosário Almeida5, Julie van der Zee6, Christine Van Broeckhoven6, Amalia C Bruni7, Maria Anfossi7, Livia Bernardi7, Raffaele Maletta7, María Serpente8, Daniela Galimberti8, Elio Scarpini8, Giacomina Rossi9, Paola Caroppo9, Luisa Benussi10, Roberta Ghidoni10, Giuliano Binetti10, Benedetta Nacmias11, Sandro Sorbi11, Irene Piaceri11, Silvia Bagnoli11, Anna Antonell12, Raquel Sánchez-Valle12, Beatriz De la Casa-Fages13, Francisco Grandas13, Mónica Diez-Fairen14, Pau Pastor14, Raffaele Ferrari15, Victoria Álvarez16, Manuel Menéndez-González17.   

Abstract

We analyzed the frequency of intermediate alleles (IAs) in the ATXN1, ATXN2, and HTT genes in several neurodegenerative diseases. The study included 1126 patients with Alzheimer's disease (AD), 440 patients with frontotemporal dementia (FTD), and 610 patients with Parkinson's disease. In all cohorts, we genotyped ATXN1 and ATXN2 CAG repeats. In addition, in the FTD cohort, we determined the number of HTT CAG repeats. The frequency of HTT IAs was higher in patients with FTD (6.9%) versus controls (2.9%) and in the C9orf72 expansion noncarriers (7.2%) versus controls (2.9%), although the difference was nonsignificant after correction for multiple testing. Compared with controls, progressive nonfluent aphasia (PNFA) groups showed a significantly higher frequency of HTT IAs (13.6% vs. 2.9% controls). For the ATXN2 gene, we observed an increase in IA frequency in AD cases (AD 4.1% vs. controls 1.8%) and in the behavioral FTD group (4.8% vs. 1.8%). For the ATXN1 gene, we found a significant increase of IAs in patients with PNFA (18.6%) versus controls (6.7%). In conclusion, our work suggests that the HTT and ATXN1 IAS may contribute to PNFA pathogenesis and point to a link between ATXN2 IAS and AD.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAG repeats; Intermediate alleles; Neurodegeneration; Tauopathies

Year:  2019        PMID: 31810584     DOI: 10.1016/j.neurobiolaging.2019.10.017

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  5 in total

Review 1.  Advancing genomic technologies and clinical awareness accelerates discovery of disease-associated tandem repeat sequences.

Authors:  Terence Gall-Duncan; Nozomu Sato; Ryan K C Yuen; Christopher E Pearson
Journal:  Genome Res       Date:  2021-12-29       Impact factor: 9.438

2.  Natural selection at the RASGEF1C (GGC) repeat in human and divergent genotypes in late-onset neurocognitive disorder.

Authors:  Z Jafarian; S Khamse; H Afshar; H R Khorram Khorshid; A Delbari; M Ohadi
Journal:  Sci Rep       Date:  2021-09-28       Impact factor: 4.996

3.  CAG Repeats Within the Non-pathological Range in the HTT Gene Influence Personality Traits in Patients With Subjective Cognitive Decline: A 13-Year Follow-Up Study.

Authors:  Valentina Moschini; Salvatore Mazzeo; Silvia Bagnoli; Sonia Padiglioni; Filippo Emiliani; Giulia Giacomucci; Carmen Morinelli; Assunta Ingannato; Tommaso Freni; Laura Belloni; Camilla Ferrari; Sandro Sorbi; Benedetta Nacmias; Valentina Bessi
Journal:  Front Psychiatry       Date:  2022-03-11       Impact factor: 4.157

4.  Brainstem atrophy is linked to extrapyramidal symptoms in frontotemporal dementia.

Authors:  Sami Heikkinen; Antti Cajanus; Kasper Katisko; Päivi Hartikainen; Ritva Vanninen; Annakaisa Haapasalo; Johanna Krüger; Anne M Remes; Eino Solje
Journal:  J Neurol       Date:  2022-04-04       Impact factor: 6.682

5.  Toxicity of pathogenic ataxin-2 in Drosophila shows dependence on a pure CAG repeat sequence.

Authors:  Leeanne McGurk; Olivia M Rifai; Oksana Shcherbakova; Alexandra E Perlegos; China N Byrns; Faith R Carranza; Henry W Zhou; Hyung-Jun Kim; Yongqing Zhu; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2021-09-15       Impact factor: 6.150

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.